Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Financial Results:
Caplin Point Laboratories Ltd reported Revenues for Q4FY25 of ₹502.00 Crores up from ₹453.00 Crore year on year, a rise of 10.82%.
Total Expenses for Q4FY25 of ₹351.00 Crores up from ₹324.00 Crores year on year, a rise of 8.33%.
Consolidated Net Profit of ₹145.00 Crores up 19.83% from ₹121.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹18.76, up 17.18% from ₹16.01 in the same quarter of the previous year.